Arcturus Therapeutics Holdings Inc. (ARCT) vs Enanta Pharmaceuticals, Inc. (ENTA)
A side-by-side comparison of Arcturus Therapeutics Holdings Inc. and Enanta Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARCT
Arcturus Therapeutics Holdings Inc.
$13.40HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
ENTA
Enanta Pharmaceuticals, Inc.
$12.22HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — ARCT vs ENTA
growth of $100 · dividends reinvested · last 10yARCT -18.2% (-2.0%/yr)ENTA -52.4% (-7.2%/yr)ARCT compounded faster over this window
ARCT ENTA
ARCT vs ENTA: by the numbers
- •ARCT is the larger company ($381M vs $355M market cap).
- •Both run net losses; ENTA's is the smaller (-96.89% vs -391.90% net margin).
- •ARCT grew revenue faster over the past five years (22.30% vs -7.65% CAGR).
Metrics side by side
Valuation
| Metric | ARCT | ENTA |
|---|---|---|
| P/S ratio | 16.00 | 5.45 |
| P/B ratio | 2.22 | 3.52 |
Profitability
| Metric | ARCT | ENTA |
|---|---|---|
| Gross margin | 95.50% | 98.15% |
| Operating margin | -111.51% | -130.65% |
| Net margin | -391.90% | -96.89% |
| ROE | -54.29% | -62.56% |
| ROIC | -54.07% | -24.20% |
Growth (annualized)
| Metric | ARCT | ENTA |
|---|---|---|
| Revenue CAGR (5Y) | 22.30% | -7.65% |
| Total return CAGR (5Y) | -18.73% | -26.94% |
Frequently asked
- Which has grown faster, ARCT or ENTA?
- Over the past five years, ARCT grew revenue faster — ARCT at a 22.30% CAGR versus ENTA at -7.65%.
- How have ARCT and ENTA total returns compared?
- Over the past 10 years, ARCT delivered -2.54% and ENTA delivered -7.11% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arcturus Therapeutics ROEEnanta Pharmaceuticals ROEArcturus Therapeutics operating marginEnanta Pharmaceuticals operating marginArcturus Therapeutics revenue growthEnanta Pharmaceuticals revenue growthArcturus Therapeutics free cash flowEnanta Pharmaceuticals free cash flow
Arcturus Therapeutics & Enanta Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.